News 2017-10-10T19:50:56+00:00

Pharma Marketing News

  1. ASH: AbbVie's Venclexta trounces chemo in Rituxan CLL combo study - December 12, 2017 at 3:38 am
    AbbVie and Roche are working to widen Venclexta&rs [...]
  2. ASH: Johnson & Johnson scores big Darzalex win in first-line myeloma, slashing risks in half - December 11, 2017 at 9:17 pm
    Johnson & Johnson has found plenty of success [...]
  3. ASH: Seattle Genetics CEO sees a big new Adcetris market, but one analyst has some doubts - December 11, 2017 at 3:17 pm
    With full data out from a trial of Seattle Genetic [...]
  4. Roche touts more Tecentriq-plus-Avastin data, this time in kidney cancer - December 11, 2017 at 3:07 pm
    Roche wants to make its immunotherapy Tecentriq an [...]
  5. ASH: J&J, AbbVie tout long-term Imbruvica data in the face of a new AstraZeneca threat - December 11, 2017 at 1:53 pm
    Johnson & Johnson and AbbVie have racked up so [...]
  6. Tax bill may target pharma's DTC deduction, but ad industry's ready to defend it - December 10, 2017 at 10:58 pm
    Direct-to-consumer advertising deductions could on [...]
  7. AstraZeneca taps Biggest Loser host Bob Harper for heart attack survivors push - December 9, 2017 at 8:47 pm
    Bob Harper knows survival. The Biggest Loser coach [...]
  8. Specialty pharmacy scrutiny hits again with state's focus on Horizon meds - December 7, 2017 at 3:02 pm
    Horizon has faced its share of trouble with formul [...]
  9. Clovis' Rubraca takes aim at Lynparza, Zejula with priority review for new use - December 6, 2017 at 2:36 pm
    Clovis Oncology is one step away from a new use fo [...]
  10. Settle down, Allergan investors. Botox's market share is safe, analysts say - December 6, 2017 at 2:28 pm
    Allergan’s investors fretted Tuesday over st [...]
  11. In a crowded market, AbbVie may still have a best-in-class psoriasis prospect up its sleeve: analyst - December 6, 2017 at 1:17 pm
    The last few years have seen a wave of new biologi [...]
  12. Johnson & Johnson, Sanofi top 'Good Pharma' trial transparency ranking with perfect scores - December 6, 2017 at 12:18 pm
    It’s an A-plus for Johnson & Johnson and [...]
  13. Should pharma embrace the dark side? If that means dark social, definitely, agency says - December 6, 2017 at 3:15 am
    Pharma has been accused of being on the dark side, [...]
  14. Novartis looks at offloading its generic pills business in U.S. as market continues to decline - December 4, 2017 at 3:34 pm
    The market for generic pills has gotten so bad in [...]
  15. Bayer pulls veil back on Xofigo-Zytiga combo study after deaths, fractures crop up - December 4, 2017 at 2:59 pm
    Bayer thought it might be able to expand Xofigo in [...]
  16. Lilly's Taltz takes Cosentyx rivalry into psoriatic arthritis with new FDA nod - December 4, 2017 at 1:30 pm
    Eli Lilly’s Taltz officially has a new arena [...]
  17. Pfizer tops Dow's intellectual heap, with J&J and Merck close behind: study - December 4, 2017 at 12:20 pm
    Pfizer is the smartest company in the Dow. That&rs [...]
  18. Social listening data is good, but it's better when combined with offline insights: agency - December 4, 2017 at 1:30 am
    The good news about social listening is that most [...]
  19. ViiV starts 'Moving Forward' into first branded TV ads for HIV treatment - December 2, 2017 at 4:40 pm
    GlaxoSmithKline's ViiV Healthcare is taking i [...]
  20. One big Novartis takeaway from Entresto's slow start? Heart failure doesn't work like oncology - November 29, 2017 at 3:03 pm
    Novartis heart failure med Entresto, which got a s [...]
Meeting Connect

Comply